SeeThruEquity, a popular independent equity research firm focused on microcap and small cap public entities reported that it released a research report on Nutra Pharma Corp. (OTCMKTS:NPHC). The research firm has a price target of $0.53 on NPHC stock. Recently the firm also issued a coverage on Propanc Health Group Corp (OTCMKTS:PPCH) with a price target of $1.52 on PPCH stock.

The expert view

Ajay Tandon, the Chief Executive of SeeThruEquity, highlighted that in their view, Nutra Pharma has taken several steps to advance the business since 2010. The company worked to increase its sales and also improved cost base and capital structure. Over the last year, the company had minimized its outstanding debt and consolidated shares to reduce the share count to 39.7 million.

On the cost front, Nutra Pharma Corp. (OTCMKTS:NPHC) recorded huge success as it successfully brought fulfillment in-house to its FL facility. The measure helped to reduce accounting as well as legal expenses. The research firm expects to witness various potential positive events over the next on year, as the company is working on expansion process of ‘Nyloxin’ distribution nationally and internationally. It had already announced expansions plans for Canada, India, and China.

The report highlights

The research firm highlighted in report that Nutra Pharma focus is on OTC product expansion that will drive its growth in coming years. They talked about company’s product portfolio of OTC alternative pain medication and lead product, ‘Nyloxin’ for severe and moderate chronic pain. It is an effective, non-opiate and non-addictive alternative to opiates and NSAIDs for the healing of chronic pain. The main ingredient in the lead product is Asian cobra venom. The sales of Nyloxin have grown considerably since the company hired Lumaxa to include the product in its vast network. Its sales have surged over 100% from 1Q2014 to 1Q2015.

In last trading session, the stock price of Nutra Pharma gained 13.50% to close the trading session at $0.185.